Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Sprycel, you must consult a qualified healthcare professional.
| 50 mg/1 | TABLET | ORAL | 0003-0528 |
| 20 mg/1 | TABLET | ORAL | 0003-0527 |
| 80 mg/1 | TABLET | ORAL | 0003-0855 |
Detailed information about Sprycel
Dasatinib is a potent second-generation tyrosine kinase inhibitor used primarily to treat certain types of leukemia, including Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.
The dosage of Dasatinib is highly individualized based on the type of leukemia being treated and the patient's response to the medication. According to clinical guidelines:
For pediatric patients (children 1 year and older), the dose is calculated based on body weight. The following is a general guideline for chronic phase CML or Ph+ ALL (in combination with chemotherapy):
Dosage may be adjusted by the pediatric oncologist based on the child's blood counts and tolerance. Dasatinib is not recommended for infants under one year of age.
Since less than 4% of Dasatinib is excreted by the kidneys, no specific dose adjustments are typically required for patients with mild to moderate renal impairment. However, clinicians exercise caution in patients with severe kidney disease as clinical data in this population is limited.
Because Dasatinib is primarily metabolized by the liver, patients with hepatic impairment (liver dysfunction) may experience higher levels of the drug in their bloodstream. While the FDA does not mandate a specific starting dose reduction for mild hepatic impairment, those with moderate to severe impairment (Child-Pugh Class B or C) should be monitored very closely, and a dose reduction may be considered by the treating physician.
No specific dose adjustment is required based solely on age. However, elderly patients (65 and older) are more likely to experience side effects such as fluid retention and shortness of breath. Close monitoring for these complications is essential in the geriatric population.
To ensure the medication works effectively, patients should follow these administration guidelines:
If you miss a dose of Dasatinib, skip the missed dose and take your next scheduled dose at the regular time. Do not take two doses at once to make up for a missed one. If you frequently forget doses, consider using a pill organizer or alarm, as consistent dosing is vital for controlling leukemia.
Signs of a Dasatinib overdose may include severe low blood counts (leading to bleeding or infection) and severe fluid retention. If an overdose is suspected, contact a Poison Control Center or seek emergency medical attention immediately. There is no specific antidote for Dasatinib; treatment is supportive and focuses on managing symptoms.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this could allow the leukemia to progress.
Dasatinib is a potent medication that affects many systems in the body. The most frequently reported side effects include:
Dasatinib is a high-risk medication that requires careful management by an oncology specialist. Patients must be aware that while this drug is effective against leukemia, it can suppress the immune system and affect organ function. It is vital to maintain all follow-up appointments and laboratory tests. You should inform all of your healthcare providers, including dentists and pharmacists, that you are taking a tyrosine kinase inhibitor.
Currently, there are no FDA black box warnings for Dasatinib. However, the FDA-approved labeling includes significant warnings regarding life-threatening pleural effusions and severe myelosuppression that require immediate clinical action if they occur.
Certain drugs should never be used with Dasatinib because they can cause life-threatening toxicity or make the Dasatinib completely ineffective:
There are very few absolute contraindications for Dasatinib, given its role in treating life-threatening cancer. However, the following apply:
These are conditions where the drug should be used with extreme caution and only after a thorough risk-benefit analysis:
Dasatinib is classified as a drug that can cause fetal harm (formerly FDA Category D). Based on its mechanism of action and findings in animal studies, Dasatinib can cause embryo-fetal toxicity when administered to a pregnant woman. There are reports of hydrops fetalis (severe swelling in the newborn) and fetal skeletal malformations in humans.
It is not known whether Dasatinib or its metabolites are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants—including severe blood count suppression—breastfeeding is not recommended
Dasatinib is a small-molecule inhibitor of multiple tyrosine kinases. Its primary target is the BCR-ABL fusion protein, which is the causative agent in Philadelphia chromosome-positive leukemias. It binds to the ATP-binding site of the BCR-ABL enzyme with a much higher affinity than Imatinib (approximately 325 times more potent in vitro).
Beyond BCR-ABL, Dasatinib inhibits the SRC family kinases (SRC, LCK, YES, FYN). SRC kinases are involved in the pathways that allow cancer cells to migrate, survive, and resist other treatments. By inhibiting SRC, Dasatinib can often overcome Imatinib resistance caused by BCR-ABL mutations (except for the T315I mutation). It also targets c-KIT, EPHA2, and PDGFRβ, which are involved in various cell signaling and growth pathways.
The relationship between Dasatinib plasma concentration and BCR-ABL inhibition is well-established. Higher concentrations lead to greater suppression of leukemic clones. The duration of kinase inhibition with once-daily dosing is sufficient to maintain clinical response, even though the drug has a short half-life. Tolerance to the therapeutic effect (where the drug stops working) is usually due to new genetic mutations in the leukemia cells rather than a change in how the body processes the drug.
Common questions about Sprycel
Dasatinib is a targeted cancer medication used to treat specific types of blood cancer in both adults and children. It is primarily prescribed for Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in all phases, including chronic, accelerated, and blast phases. Additionally, it is used to treat Ph+ acute lymphoblastic leukemia (ALL) in patients who have not responded well to other treatments. The drug works by blocking the BCR-ABL protein, which is responsible for the overproduction of abnormal white blood cells. Because it targets specific cancer proteins, it is considered a precision medicine rather than a traditional broad-spectrum chemotherapy.
The most common side effects reported by patients taking Dasatinib include fluid retention, which can cause swelling in the legs or fluid around the lungs (pleural effusion). Many patients also experience gastrointestinal issues such as diarrhea, nausea, and abdominal pain. Significant changes in blood counts are very common, leading to anemia, increased infection risk, and easy bruising. Other frequent complaints include headaches, fatigue, and muscle or joint pain. Most of these side effects are manageable with supportive care or dose adjustments by your oncologist.
There is no known direct chemical interaction between alcohol and Dasatinib that would make the drug stop working. However, both alcohol and Dasatinib are processed by the liver, and combining them may increase the risk of liver strain or toxicity. Alcohol can also worsen certain side effects of Dasatinib, such as dehydration from diarrhea or dizziness. It is generally recommended to limit alcohol consumption to moderate levels and to consult your doctor about your specific health status. If you have pre-existing liver issues, your doctor may advise you to avoid alcohol entirely during treatment.
No, Dasatinib is not considered safe during pregnancy and is known to cause significant fetal harm. Based on animal studies and limited human data, exposure to Dasatinib during pregnancy can lead to skeletal malformations and other developmental toxicities. Women of childbearing age must use highly effective contraception during treatment and for at least 30 days after stopping the drug. If you become pregnant while taking Dasatinib, you must inform your oncologist immediately to discuss the risks. Breastfeeding is also discouraged while taking this medication as it may pass into breast milk.
Dasatinib begins working at the molecular level within hours of the first dose, but measurable clinical results take longer to appear. Most patients will see an improvement in their white blood cell counts within the first 2 to 4 weeks of therapy. A 'complete hematologic response' (normal blood counts) usually occurs within 3 months. Achieving a 'major molecular response,' where the BCR-ABL gene levels drop significantly, typically takes 6 to 12 months of consistent daily use. Your doctor will use specialized blood tests called PCR tests to monitor this progress over time.
You should never stop taking Dasatinib suddenly without direct instructions from your oncologist. Discontinuing a tyrosine kinase inhibitor can allow the leukemia cells to begin multiplying again, potentially leading to a relapse of the disease. In some cases, stopping the drug can cause the cancer to return in a more aggressive, resistant form. If you are experiencing severe side effects, your doctor will likely lower your dose or provide a supervised 'drug holiday' rather than having you stop abruptly. Always follow the specific tapering or discontinuation plan provided by your medical team.
If you miss a dose of Dasatinib, you should simply skip the missed dose and take your next dose at its regularly scheduled time. Do not take two doses at once to make up for the one you missed, as this significantly increases the risk of toxicity and heart rhythm issues. Consistency is key for controlling leukemia, so try to take your medication at the same time every day. If you find yourself missing doses frequently, talk to your healthcare provider about strategies to improve adherence. If you accidentally take too much, seek emergency medical help immediately.
Dasatinib can cause weight gain, but it is usually not due to an increase in body fat. Instead, weight gain is often a sign of fluid retention, which is a common side effect of the drug. This fluid can accumulate in the legs (peripheral edema) or, more seriously, around the lungs or heart. If you notice a sudden increase in weight—such as 3 to 5 pounds in a week—along with shortness of breath or swelling, you should contact your doctor immediately. This type of weight gain often requires treatment with diuretic medications (water pills) or a temporary dose reduction.
Dasatinib has many significant drug interactions, particularly with medications that affect stomach acid or liver enzymes. Drugs that reduce stomach acid, like proton pump inhibitors (omeprazole), can prevent Dasatinib from being absorbed properly. Additionally, many common medications like certain antibiotics, antifungals, and heart medicines can change the levels of Dasatinib in your blood. You must provide your oncologist and pharmacist with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking. They will check for interactions and may adjust your dosages accordingly.
Yes, generic versions of Dasatinib have been approved by the FDA and are becoming increasingly available in various markets. The generic version contains the same active ingredient and meets the same bioequivalence standards as the brand-name version, Sprycel. Availability may depend on your specific insurance plan and the patent status in your region. Using a generic version can significantly reduce the cost of treatment for many patients. Always ensure that the generic tablets are handled with the same precautions as the brand name, including swallowing them whole and avoiding contact with broken tablets.
Other drugs with the same active ingredient (Dasatinib)
> Warning: Stop taking Dasatinib and call your doctor immediately if you experience any of these serious symptoms:
Prolonged use of Dasatinib can lead to chronic issues. The most significant concern is the cumulative risk of pleural effusions, which may require repeated medical procedures to drain the fluid. There is also a risk of cardiovascular events, including atherosclerosis (hardening of the arteries), which requires long-term monitoring of cholesterol and blood pressure. Additionally, long-term TKIs may affect bone metabolism, though this is still being studied in adult populations.
As of 2024, Dasatinib (Sprycel) does not carry an FDA Black Box Warning. However, it does carry several 'Warnings and Precautions' that are considered nearly as critical, particularly regarding myelosuppression and fluid retention. Healthcare providers treat these with the highest level of vigilance, often performing weekly blood counts during the first two months of therapy.
Report any unusual symptoms to your healthcare provider immediately. Early intervention for side effects often allows patients to remain on the medication at a lower dose rather than discontinuing it entirely.
To ensure safety, your doctor will require the following tests:
Dasatinib may cause dizziness or blurred vision in some patients. Do not drive or operate heavy machinery until you know how the medication affects you. If you experience significant fatigue or 'brain fog,' use caution when performing tasks that require alertness.
There is no direct contraindication between Dasatinib and moderate alcohol consumption. However, alcohol can strain the liver, which is already processing the Dasatinib. Furthermore, alcohol can worsen the dehydration associated with diarrhea. It is best to limit alcohol intake and discuss your habits with your oncologist.
Do not stop taking Dasatinib suddenly. Stopping a TKI can lead to a 'rebound' effect where the leukemia cells begin to multiply rapidly again. If the drug must be stopped due to toxicity, your doctor will provide a specific plan. There is no traditional 'withdrawal syndrome,' but the risk of cancer progression is the primary concern upon discontinuation.
> Important: Discuss all your medical conditions, especially heart, liver, or lung disease, with your healthcare provider before starting Dasatinib.
Dasatinib does not typically interfere with the chemical assays of most lab tests, but it will profoundly change the results of blood tests (e.g., lowering white blood cell counts). It may also cause false elevations in serum creatinine in rare instances due to competition for renal transport, though this is not a common clinical concern.
For each major interaction, the mechanism usually involves the Cytochrome P450 3A4 enzyme system. Inhibition of this enzyme leads to toxic accumulation, while induction leads to therapeutic failure. Management strategies usually involve selecting alternative non-interacting medications or preemptively adjusting the Dasatinib dose by 20-50% under strict oncology supervision.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even over-the-counter vitamins can change how Dasatinib works.
While Dasatinib is chemically distinct from other TKIs like Imatinib (Gleevec) or Nilotinib (Tasigna), some patients who experience severe skin rashes or liver toxicity with one TKI may experience a similar reaction with another. However, many patients who are 'intolerant' to Imatinib (meaning they had bad side effects) can tolerate Dasatinib quite well. There is no known cross-reactivity with common antibiotics or non-cancer medications.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to cancer therapies, before prescribing Dasatinib.
Dasatinib is FDA-approved for use in children 1 year of age and older for Ph+ CML in the chronic phase and Ph+ ALL (in combination with chemotherapy).
In clinical trials, approximately 10-15% of patients were 65 years of age or older. While the effectiveness of the drug is similar across age groups, elderly patients are more likely to experience side effects, particularly:
Physicians often start elderly patients on the standard dose but have a lower threshold for reducing the dose if side effects appear.
Specific studies in patients with decreased renal function have not been conducted. However, since renal excretion is a minor route of elimination, no dose adjustment is generally recommended for patients with kidney disease. Patients on dialysis do not require supplemental doses as the drug is highly protein-bound and not likely to be cleared by the dialysis machine.
Dasatinib is primarily metabolized by the liver. Patients with moderate to severe hepatic impairment should be treated with caution. The exposure to the drug can be increased in these patients, raising the risk of toxicity. Your doctor may perform more frequent liver function tests and may consider a lower starting dose if you have significant liver scarring (cirrhosis).
> Important: Special populations require individualized medical assessment. Always disclose your full health status to your oncology team.
| Parameter | Value |
|---|---|
| Bioavailability | Variable (pH dependent) |
| Protein Binding | ~96% (to Albumin) |
| Half-life | 3 to 5 hours |
| Tmax | 0.5 to 3 hours |
| Metabolism | Hepatic (Primary CYP3A4) |
| Excretion | Fecal 85%, Renal 4% |
Dasatinib is classified as a Second-Generation Tyrosine Kinase Inhibitor (TKI). It is part of the broader category of targeted therapies or 'precision medicine' in oncology. Related medications in this class include Nilotinib (Tasigna), Bosutinib (Bosulif), and Ponatinib (Iclusig).